Allogenetics
Private Company
Total funding raised: $1.5M
Overview
Allogenetics is a preclinical-stage biotech founded in 2021, developing a first-in-class therapeutic platform to engineer donor organs for immunological invisibility. The company's core technology involves the ex vivo genetic modification of organs to silence the expression of Human Leukocyte Antigen (HLA) proteins, thereby preventing recognition and rejection by the recipient's immune system without the need for chronic immunosuppression. Founded by leading experts in transplant engineering and immunology, the company is based on pioneering academic research. If successful, this approach could fundamentally transform the standard of care in solid organ transplantation.
Technology Platform
Ex vivo genetic modification platform for donor organs using viral transduction during machine perfusion to permanently silence expression of Major Histocompatibility Complex (MHC/HLA) proteins, aiming to render organs 'immunologically invisible' to the recipient's immune system.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
The competitive landscape includes companies developing tolerance-inducing cell therapies (e.g., Sangamo/Pfizer, Quell Therapeutics) and next-generation immunosuppressants. However, Allogenetics' approach of directly engineering the donor organ for invisibility is a distinct and first-in-class strategy, with few, if any, direct competitors at a similar stage.